233 related articles for article (PubMed ID: 11900675)
1. Predicting and preventing post-ERCP pancreatitis.
Baillie J
Curr Gastroenterol Rep; 2002 Apr; 4(2):112-9. PubMed ID: 11900675
[TBL] [Abstract][Full Text] [Related]
2. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
4. [Can post-ERCP acute pancreatitis be predicted and prevented?].
Heyries L
Gastroenterol Clin Biol; 2001 Jan; 25(1 Suppl):1S241-6. PubMed ID: 11223596
[No Abstract] [Full Text] [Related]
5. Prevention of post-ERCP pancreatitis.
Haber GB
Gastrointest Endosc; 2000 Jan; 51(1):100-3. PubMed ID: 10625814
[No Abstract] [Full Text] [Related]
6. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
7. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis.
Oezcueruemez-Porsch M; Kunz D; Hardt PD; Fadgyas T; Kress O; Schulz HU; Schnell-Kretschmer H; Temme H; Westphal S; Luley C; Kloer HU
Dig Dis Sci; 1998 Aug; 43(8):1763-9. PubMed ID: 9724166
[TBL] [Abstract][Full Text] [Related]
9. What are the predictors of post-ERCP pancreatitis, and how useful are they?
Sultan S; Baillie J
JOP; 2002 Nov; 3(6):188-94. PubMed ID: 12432185
[TBL] [Abstract][Full Text] [Related]
10. Early successes and late failures in the prevention of post endoscopic retrograde cholangiopancreatography.
Lieb JG; Draganov PV
World J Gastroenterol; 2007 Jul; 13(26):3567-74. PubMed ID: 17659706
[TBL] [Abstract][Full Text] [Related]
11. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
13. Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.
Mansour-Ghanaei F; Joukar F; Taherzadeh Z; Sokhanvar H; Hasandokht T
World J Gastroenterol; 2016 Jun; 22(21):5114-21. PubMed ID: 27275104
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
15. Preventing post-ERCP pancreatitis: where are we?
Testoni PA
JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013
[TBL] [Abstract][Full Text] [Related]
16. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
17. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
Katsinelos P; Fasoulas K; Paroutoglou G; Chatzimavroudis G; Beltsis A; Terzoudis S; Katsinelos T; Dimou E; Zavos C; Kaltsa A; Kountouras J
Endoscopy; 2012 Jan; 44(1):53-9. PubMed ID: 22198776
[TBL] [Abstract][Full Text] [Related]
18. NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy.
NIH Consens State Sci Statements; 2002 Jan 14-16; 19(1):1-26. PubMed ID: 14768653
[TBL] [Abstract][Full Text] [Related]
19. Use of the urinary trypsinogen-2 dip stick test in early diagnosis of pancreatitis after endoscopic retrograde cholangiopancreatography.
Sankaralingam S; Wesen C; Barawi M; Galera R; Lloyd L
Surg Endosc; 2007 Aug; 21(8):1312-5. PubMed ID: 17332967
[TBL] [Abstract][Full Text] [Related]
20. Repeated Negative Urine Trypsinogen-2 Dipstick Test Rules Out Diagnosis of Post-ERCP Pancreatitis.
Rainio M; Lindström O; Udd M; Puolakkainen P; Stenman UH; Kylänpää L
J Clin Gastroenterol; 2021 Apr; 55(4):361-366. PubMed ID: 32925303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
